Open

Testing Nivolumab and Ipilimumab Immunotherapy With or Without Cabozantinib

To determine if the progression-free survival (PFS) of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Extended hours (M-F, early morning or evening)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of the study team and answer questions about your health and have your vitals taken. The study also involves blood draws, CT scan(s), and willingness to take the study medication regularly.

Incentives

In-person visits:
About 15

Total length of participation:
About 2 years

Looking for Specific Volunteers

Able to participate:

You have documentation of Nasopharyngeal Carcinoma
You are able to swallow study medication
You do not have any comorbid conditions
You are at least 18 years old
You have adequate organ and marrow function

Not eligible if:

You have had more than 2 prior lines of prior systemic therapy for recurrent, metastatic Nasopharyngeal Carcinoma.
You are pregnant or nursing
You received chemotherapy or radiotherapy within 4 weeks of enrolling
You have prior malignancy
You have an active autoimmune disease

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

NC Memorial Hospital
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Sid Sheth
Lineberger Comprehensive Cancer Center

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Head and Neck)

IRB Number

23-2643

ClinicalTrials.gov

NCT06010095

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.